10 May 2024
10 May 2024
Workforce optimisation, R&D prioritisation and technology investments are on Takeda’s agenda.
The centre of gravity in the pharmaceutical industry is changing. But one common factor can help make supply chains more comprehensible, resilient and valuable: data
The company may make upfront, development, and commercial milestone payments of $600m.
Marinus expects to share data from the Phase III RAISE trial of IV ganaxolone for the treatment of status epilepticus later in the summer.
Clobetasol propionate ophthalmic suspension obtained FDA approval in March 2024.
Acumen’s trial for sabirnetug is currently enrolling patients with early Alzheimer’s disease at sites in the US and Canada.
Rakovina has expanded research collaborations with Pharma Inventor and the University of British Columbia to identify novel drug candidates.
The Danish biotech will focus on developing antibody therapies to treat cancer and autoimmune diseases
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
